Nektar Therapeutics (NKTR) Accounts Payables (2010 - 2026)

Nektar Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 43.78% year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 43.78% decrease from a year earlier, with the FY2025 full-year figure at $10.8 million, down 6.83% from the prior year.
• Accounts Payables slipped to $10.0 million in Q1 2026 per NKTR's latest filing, from $10.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.8 million in Q1 2025 and bottomed at $2.6 million in Q2 2023.
• The 5-year median for Accounts Payables is $10.0 million (2026), against an average of $9.8 million.
• Across the five-year window, Accounts Payables tumbled 78.79% in 2023 and surged 160.86% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $13.0 million in 2022, then declined by 24.13% to $9.8 million in 2023, then advanced by 17.38% to $11.6 million in 2024, then fell by 6.83% to $10.8 million in 2025, then dropped by 6.91% to $10.0 million in 2026.
• Per Business Quant, the three latest NKTR Accounts Payables figures stand at $10.0 million (Q1 2026), $10.8 million (Q4 2025), and $15.6 million (Q3 2025).